Bioceltix Altman Z-Score
The Altman Z-Score of Bioceltix (BCX.WA) as of Oct 30, 2026 is 119.89. In the previous year, Altman Z-Score was 80.90 — a change of 48.19% (higher).
Get this data via API
Financial Data API
Altman Z-Score
119.89
YoY
48.19%
Last updated:
Altman Z-Score of Bioceltix is 2025 119.89 . Altman Z-Score of Bioceltix was 2024 80.90 . It decreases by 48.19% higher compared to the previous year.
The Bioceltix Altman Z-Score history
3 Years
10 Years
25 Years
Max
Altman Z-Score
Date
Altman Z-Score
Jan 1, 2018
162.33 PLN
Jan 1, 2019
210.06 PLN
Jan 1, 2020
188.24 PLN
Jan 1, 2021
125.54 PLN
Jan 1, 2022
105.20 PLN
Jan 1, 2023
119.93 PLN
Jan 1, 2024
80.90 PLN
Jan 1, 2025
119.89 PLN
| YEAR | Altman Z-Score | YoY |
|---|---|---|
| 119.89 | +48.19% | |
| 80.90 | -32.54% | |
| 119.93 | +14.00% | |
| 105.20 | -16.20% | |
| 125.54 | -33.31% | |
| 188.24 | -10.39% | |
| 210.06 | +29.40% | |
| 162.33 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bioceltix Stock analysis
What does Bioceltix do? Bioceltix SA focuses on research and development within the field of veterinary medicine, specifically targeting the treatment of companion animals. The company develops candidates for veterinary medicinal products by utilizing the immunomodulatory properties of mesenchymal stem cells as the active substance. This scientific approach allows the firm to conduct research and development works that facilitate clinical trials and the full registration of these medicinal products with the European Medicines Agency, adhering to standards similar to those for human medicines. Bioceltix is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Bioceltix stock
Altman Z-Score of Bioceltix is 119.89 in 2025.
On Eulerpool you can find the complete historical development of Altman Z-Score Bioceltix since 2006 – with annual values, charts, and detailed analysis.
The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Bioceltix
All Key Metrics — Bioceltix
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth